Search

Your search keyword '"Grayson, Peter C."' showing total 241 results

Search Constraints

Start Over You searched for: Author "Grayson, Peter C." Remove constraint Author: "Grayson, Peter C." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
241 results on '"Grayson, Peter C."'

Search Results

1. Automated Plaque Detection and Agatston Score Estimation on Non-Contrast CT Scans: A Multicenter Study

4. Venous and arterial thrombosis in patients with VEXAS syndrome

5. Takayasu’s Arteritis

6. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS

7. Spectrum of clonal hematopoiesis in VEXAS syndrome

11. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis

12. Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis

14. Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study.

17. ACR Appropriateness Criteria® Noncerebral Vasculitis

21. Development of the Takayasu's Arteritis Integrated Disease Activity Index

22. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu’s arteritis, ANCA-associated vasculitis and giant cell arteritis

25. Large-vessel vasculitis

27. Mitochondrial-mediated inflammation and platelet activation in giant cell arteritis

28. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

31. Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis

32. Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism

33. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica

34. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

35. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population

39. Clonal Hematopoiesis in a Broad Age Spectrum of Systemic Vasculitis

40. Eosinophilia in Vexas Syndrome: Expanding Hematologic Phenotype

41. DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways

42. Clonal Hematopoiesis in Vexas Syndrome

43. Thrombotic Manifestations in Patients with Vexas Syndrome

44. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis

45. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis

47. Reply

48. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

49. Genomic ascertainment for UBA1 variants and VEXAS syndrome: a population-based study

50. Reply.

Catalog

Books, media, physical & digital resources